Department of Molecular and Integrative Physiology and University of Michigan, Ann Arbor, Michigan, USA.
Department of Biomedical Engineering, University of Michigan, Ann Arbor, Michigan, USA.
Tissue Eng Part A. 2020 Aug;26(15-16):837-851. doi: 10.1089/ten.TEA.2019.0288. Epub 2020 Feb 28.
Much effort has been made to fabricate engineered tissues on a scale that is clinically relevant to humans; however, scale-up remains one of the most significant technological challenges of tissue engineering to date. To address this limitation, our laboratory has developed tissue-engineered skeletal muscle units (SMUs) and engineered neural conduits (ENCs), and modularly scaled them to clinically relevant sizes for the treatment of volumetric muscle loss (VML). The goal of this study was to evaluate the SMUs and ENCs , and to test the efficacy of our SMUs and ENCs in restoring muscle function in a clinically relevant large animal (sheep) model. The animals received a 30% VML injury to the peroneus tertius muscle and were allowed to recover for 3 months. The animals were divided into three experimental groups: VML injury without a repair (VML only), repair with an SMU (VML+SMU), or repair with an SMU and ENC (VML+SMU+ENC). We evaluated the SMUs before implantation and found that our single scaled-up SMUs were characterized by the presence of contracting myotubes, linearly aligned extracellular matrix proteins, and Pax7 satellite cells. Three months after implantation, we found that the repair groups (VML+SMU and VML+SMU+ENC) had restored muscle mass and tetanic force production to a level that was statistically indistinguishable from the uninjured contralateral muscle after 3 months . Furthermore, we demonstrated the ability of our ENCs to effectively bridge the gap between native nerve and the repair site by eliciting a muscle contraction through direct electrical stimulation of the re-routed nerve. Impact statement The fabrication of tissues of clinically relevant sizes is one of the largest obstacles preventing engineered tissues from achieving widespread use in the clinic. This study aimed to combat this limitation by developing a fabrication method to scale-up tissue-engineered skeletal muscle for the treatment of volumetric muscle loss in a large animal (sheep) model and evaluating the efficacy of the tissue-engineered constructs after a 3-month recovery.
已经付出了大量努力来制造具有临床相关性的工程化组织;然而,迄今为止,扩大规模仍然是组织工程面临的最重大技术挑战之一。为了解决这一限制,我们的实验室已经开发出组织工程化骨骼肌单元 (SMU) 和工程化神经导管 (ENC),并对其进行了模块化扩展,使其达到治疗体积性肌肉损失 (VML) 的临床相关尺寸。本研究的目的是评估 SMU 和 ENC,并测试我们的 SMU 和 ENC 在恢复临床相关大型动物(绵羊)模型中肌肉功能的功效。动物接受了腓骨肌第三肌 30%的 VML 损伤,并允许其恢复 3 个月。动物分为三个实验组:无修复 VML 损伤(仅 VML)、用 SMU 修复(VML+SMU)或用 SMU 和 ENC 修复(VML+SMU+ENC)。我们在植入前评估了 SMU,并发现我们单个扩展的 SMU 具有收缩肌管、线性排列的细胞外基质蛋白和 Pax7 卫星细胞的特征。植入 3 个月后,我们发现修复组(VML+SMU 和 VML+SMU+ENC)已经恢复了肌肉质量和强直力产生,与未受伤的对侧肌肉在 3 个月后没有统计学差异。此外,我们通过直接对重新布线的神经进行电刺激来诱发肌肉收缩,证明了我们的 ENC 有效地将神经与修复部位连接起来的能力。影响声明具有临床相关性的组织的制造是阻止工程化组织在临床上广泛应用的最大障碍之一。本研究旨在通过开发一种扩大组织工程化骨骼肌的制造方法来治疗大型动物(绵羊)模型中的体积性肌肉损失,并在 3 个月的恢复后评估组织工程化构建体的功效来克服这一限制。